- Home
- ZBIO vs POET Comparison
ZBIO vs POET Comparison
Compare ZBIO & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- POET
- Stock Information
- Founded
- ZBIO 2019
- POET 1972
- Country
- ZBIO United States
- POET Canada
- Employees
- ZBIO N/A
- POET N/A
- Industry
- ZBIO
- POET Semiconductors
- Sector
- ZBIO
- POET Technology
- Exchange
- ZBIO NYSE
- POET Nasdaq
- Market Cap
- ZBIO 389.2M
- POET 369.0M
- IPO Year
- ZBIO 2024
- POET N/A
- Fundamental
- Price
- ZBIO $9.80
- POET $4.13
- Analyst Decision
- ZBIO Strong Buy
- POET Strong Buy
- Analyst Count
- ZBIO 7
- POET 2
- Target Price
- ZBIO $32.29
- POET $6.25
- AVG Volume (30 Days)
- ZBIO 131.3K
- POET 777.7K
- Earning Date
- ZBIO 05-15-2025
- POET 05-14-2025
- Dividend Yield
- ZBIO N/A
- POET N/A
- EPS Growth
- ZBIO N/A
- POET N/A
- EPS
- ZBIO N/A
- POET N/A
- Revenue
- ZBIO $15,000,000.00
- POET $199,477.00
- Revenue This Year
- ZBIO N/A
- POET $10,294.19
- Revenue Next Year
- ZBIO N/A
- POET $788.30
- P/E Ratio
- ZBIO N/A
- POET N/A
- Revenue Growth
- ZBIO N/A
- POET N/A
- 52 Week Low
- ZBIO $5.83
- POET $1.65
- 52 Week High
- ZBIO $26.25
- POET $7.79
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- POET 50.31
- Support Level
- ZBIO N/A
- POET $4.06
- Resistance Level
- ZBIO N/A
- POET $4.59
- Average True Range (ATR)
- ZBIO 0.00
- POET 0.26
- MACD
- ZBIO 0.00
- POET -0.03
- Stochastic Oscillator
- ZBIO 0.00
- POET 38.67
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About POET POET Technologies Inc.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.